1. Introduction

There is a close link between the heart and kidney: cardiovascular damage drives a worsening of kidney function; in turn kidney failure worsens cardiovascular injury [1]. Heart Failure (HF) affects 5.8 million people within the USA, and over 23 million worldwide [2]. Approximately 20–30% of patients admitted for acute decompensated HF will suffer a decline in kidney function while hospitalized, and 40–60% of patients with chronic HF have CKD. The coexistence of these two diseases worsens their prognoses [3,4].

Cardiorenal syndrome (CRS) is a multi-organ disease that includes a spectrum of disorders resulting from the close interaction between the heart and kidney during acute or chronic dysfunction of one of these organs.

It was described for the first time by Robert Bright, in 1836, who found cardiac structural changes in a patient with advanced renal failure [5]. Since then, several cases have been reported, and the knowledge of its pathophysiology has gradually led to a better clinical classification of the syndrome. In 2004, the Working Group of the National Heart, Lung, and Blood Institute defined, for the first time, CRS as “the result of interactions between the kidneys and other circulatory compartments that increase circulating volume, which exacerbates the symptoms of heart failure and disease progression” [6]. In this context, the heart is considered to be the main actor, and in which the decline of renal function worsens the congestive symptoms of HF.

In 2008, the Acute Dialysis Quality Initiative divided CRS patients into two groups based on the primary organ failure driving the disease process (cardiorenal or renocardiac) [7]. This classification was further elaborated and arranged into five groups according to clinical presentations to facilitate the early differential diagnosis and the most appropriate therapy ( Figure 1 ), and biomarkers may represent decisive prognostic factors in assessing risk prediction in patients with HF and impaired kidney function.

Figure 1. Different Types of Cardiorenal Syndromes. CRS presents five subtypes characterized by the influence of chronic or acute dysfunction of one organ on another. The acute dialysis quality initiative classification of CRS is helpful to drive the clinicians to the best therapeutic strategies depending on the primum movens of the syndrome. The complex interconnection of this condition is characterized by oxidative stress and inflammation-driven damage.

2. Pathophysiology of Cardiorenal Syndrome

In acute decompensated heart failure, the cardiac pump cannot maintain optimal blood flow, resulting in volume overload and increased central venous pressure (CVP). CVP is the thoracic vena cava’s pressure near the right atrium. It indicates the blood volume returning to the heart and its ability to pump the blood back into the arterial system. When this mechanism fails, consequent venous congestion results in renal dysfunction caused by reduced renal blood flow and glomerular filtration rate (GFR), and decreased urine output.

Classical biomarkers for the assessment of kidney function include serum creatinine (SCr), albuminuria, and cystatin C (CysC), as well as urine output and eGFR. Urine and serum biomarkers, including urinary angiotensinogen, urinary enzyme N-acetyl-β-d-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), interleukin 18 (IL-18) , high sensitivity troponin I (hs-cTnI), and kidney injury molecule 1 (KIM-1) measured at the time of CRS diagnosis show improved risk stratification in determining which patients will experience adverse outcomes [13]. Among these, NGAL is the most widely used, and its urinary determination has been found to be more sensitive and specific than even plasma NGAL [14]. The increase in NGAL levels has a predictive role for the onset of acute renal injury, considerably anticipating the increase of creatinine serum levels and thus allowing prompt preventive therapeutic strategies [15].

In CRS the increased oxidative stress is also related to ischemic injury and venous congestion, resulting in the reduction of fatty acid oxidation in favor of glycolysis in myocytes. These metabolism alterations lead to a reduction in ATP production, in turn leading to major susceptibility to hypoxemia, apoptosis, and cellular death. In addition, the reduced metabolism of fatty acid oxidation leads to an increase of free fatty acid and subsequent lipotoxicity.

Increased synthesis of pro-inflammatory mediators is known in CKD and HF to promote tissue damage, and lead to cell death and fibrosis. Cytokines, also induced through the extra-hemodynamic effects of angiotensin II, are fundamental in explaining the inflammatory mechanisms involved in CRS [38]. C-reactive protein (CRP), a non-specific inflammation protein, is frequently increased in CRS. It is associated with the activation of the complement system and tissue factor production. A study of acute decompensated heart failure syndromes prospectively assessed 4269 hospitalized AHF. In these patients, elevated CRP was independently associated with higher mortality (adjusted hazard ratio [HR], 1.68) [39].

3. Neurohormonal Dysregulation

Both HF and CKD are characterized by abnormal alteration of the sympathetic nervous system (SNS). Sympathetic hyperactivity is usually a compensatory system in the
acute phases of CVD that, continuing over time, has cardio and nephrotoxic effects [26].
In CKD, in addition to up-regulation of the renin-angiotensin-aldosterone system (RAAS),
sympathetic hyperactivation causes desensitization of cardiac beta-adrenergic receptors;
furthermore, catecholamine clearance is reduced, resulting in a self-deteriorating cycle
that worsens the GFR itself, and a progression of heart failure [27,28].The direct effects of
sympathetic hyperactivation also include the alteration of cardiac calcium homeostasis,
increased hypertrophy, and apoptosis of myocytes. This results in the increased predisposition to the chronicization of cardiac remodeling [29]. Indirect effects are essentially
mediated by inflammatory molecules, such as cytokines [30].
RAAS activation has important effects in the pathogenesis of CRS. The hypoperfusion of peripheral tissue in HF determines the sympathetic nervous system’s overactivity,
with increased renin release from the juxtamedullary apparatus. Renin synthesis is also
stimulated by the reduction of hydrostatic pressure at glomerular afferent arterioles, and a
reduction of sodium delivered to the macula densa. The result of renin release is the increased production of angiotensin II, which causes renal efferent arteriolar vasoconstriction,
increasing the hydrostatic pressure inside the glomerulus to keep the GFR stable. Consequently, it decreases the peritubular hydrostatic pressure, and enhances the reabsorption of
sodium in the proximal tubules. Furthermore, angiotensin II stimulates the synthesis of
aldosterone, which in turn increases the reabsorption of sodium in the distal tubule and
increases the endothelin-1 in the kidney, a potent vasoconstrictor, proinflammatory, and
profibrotic peptide. Angiotensin II also plays a role in other tissues, especially in the heart,
where it promotes the process of remodeling and fibrosis.
Dysregulation of adenosine and arginine vasopressin (AVP) is also implicated in the
neurohormonal pathogenesis of CRS. Adenosine is generated by enzymatic degradation
of adenosine triphosphate. It is released when there is an increment of sodium levels
in the distal tubule. After binding to A1 receptors, it causes vasoconstriction of afferent
arterioles, reducing renal blood flow. Activation of A2 receptors stimulates renin secretion,
increasing sodium reabsorption in the proximal tubule and decreasing the glomerular
filtration. The use of drugs that block adenosine receptors can be useful in improving renal
function. Unfortunately, clinical trials have failed to demonstrate the beneficial support
of this therapy in reducing death and hospitalization, and improving heart and kidney
function [31].
AVP is a peptide synthesized in the supraoptic and paraventricular nuclei of the
hypothalamus that is stored in the posterior pituitary gland until released into the blood
based on the serum osmolality. It increases the solute-free water reabsorption in the distal
tubule of the kidney promoting aquaporin 2 (AQP2) movement from the intracellular
compartment to the apical membrane. AQP2 is a water channel that drives water into the
cell according to the osmotic gradient. In addition, AVP causes arteriole vasoconstriction,
which increases vascular resistance. This mechanism leads to an increase in venous return
to the heart, which worsens venous congestion. On the other hand, the vasoconstriction
reduces kidney perfusion, resulting in GFR reduction. Several studies have evaluated the
efficacy of tolvaptan, a selective, competitive AVP receptor antagonist, in CRS. The most
important trial (EVEREST) recruited 4133 patients with ADHF, and found that early use of
tolvaptan was linked to a lower mean body weight and ameliorated clinical symptomatology. Nevertheless, compared with placebo, tolvaptan effected no difference in longterm outcomes [32]. Based on the pathophysiology of the CRS, much attention was paid to
AVP as a biomarker. However, the measured values of AVP are not always reliable [29].

4. Endothelial Dysfunction and Atherosclerosis

The neurohormonal dysregulation and the accumulation of the uremic toxins in CRS
play an important role in the development of oxidative stress. The alteration of balance
between oxidant and antioxidant agents results in an increased concentration of reactive
oxygen species (ROS), leading to cellular damage and endothelial dysfunction.
Endothelial dysfunction is another important commonality between chronic kidney
disease (CKD) and HF. Endothelial cells are responsible for the functional vascular response
to hemodynamic and oxidative stress [34]. The anti-inflammatory, antioxidant action, and
vascular tone regulation of the endothelium-derived relaxing factor (EDRF) are dysregulated in both HF and CKD independent of each other [35]. Endothelial dysfunction, on the
other hand, is an early marker of atherosclerosis. Arteriosclerotic vascular disease (ASVD)
plays a primary role in the pathogenesis of CRS. As is well known, ASVD (and consequent
ischemic coronary artery disease) is both the main cause of HF and one of the main causes
of ischemic renal failure [36]. The increased cardiovascular (CV) risk related to CKD is
partly linked to a more intense and faster development of atherosclerosis, independent of
the other risk factors [37].

5. Oxidative Stress and Inflammation

In CRS the increased oxidative stress is also related to ischemic injury and venous
congestion, resulting in the reduction of fatty acid oxidation in favor of glycolysis in
myocytes. These metabolism alterations lead to a reduction in ATP production, in turn
leading to major susceptibility to hypoxemia, apoptosis, and cellular death. In addition,
the reduced metabolism of fatty acid oxidation leads to an increase of free fatty acid and
subsequent lipotoxicity.
Increased synthesis of pro-inflammatory mediators is known in CKD and HF to
promote tissue damage, and lead to cell death and fibrosis. Cytokines, also induced
through the extra-hemodynamic effects of angiotensin II, are fundamental in explaining the
inflammatory mechanisms involved in CRS [38]. C-reactive protein (CRP), a non-specific
inflammation protein, is frequently increased in CRS. It is associated with the activation
of the complement system and tissue factor production. A study of acute decompensated
heart failure syndromes prospectively assessed 4269 hospitalized AHF. In these patients,
elevated CRP was independently associated with higher mortality (adjusted hazard ratio
[HR], 1.68) [39].
As is well known, prolonged inflammation is often capable of inducing anemia in
predisposed individuals. Anemia is a common characteristic of CKD and HF patients,
with a prevalence between 5% and 55% [40], and represents an independent risk factor
for mortality [41]. It contributes to CRS development in several ways: reduced oxygen
delivery, reduced antioxidants synthesized from red blood cells, activation of sympathetic
nervous system (SNS), RAAS, AVP because of tissue ischemia that leads to vasoconstriction,
salt-water retention, and venous congestion. The role of erythropoiesis-stimulation agents
(ESAs) in the treatment of CRS is controversial. A randomized double-blind controlled
study demonstrated that improvement in hemoglobin levels with ESAs and oral iron over
one year led to an increase in cardiac function compared with oral iron therapy alone [42].
On the contrary, a trial with a higher hemoglobin level (>13.5 gr/dl) as target found an
association with a higher rate of adverse events and no improvement in the quality of
life [43].
Finally, there is burgeoning interest in the adoption of parenteral iron to improve
anemia in patients with congestive HF. Several studies [44] have reported that patients
treated with intravenous iron develop symptomatic improvement and increased exercise
capacity independent of hemoglobin level effects. These findings indicate that intravenous
iron therapy can be a promising option for the treatment of CRS.

This entry is adapted from the peer-reviewed paper 10.3390/biom11111581